BiotechTube

Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Typhoid Vaccination

Conditions

Typhoid Vaccination, Typhoid, Typhoid Fever

Trial Timeline

Apr 1, 2025 → May 30, 2026

NCT ID
NCT06757283

About Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV

Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV is a phase 3 stage product being developed by Zydus Lifesciences for Typhoid Vaccination. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06757283. Target conditions include Typhoid Vaccination, Typhoid, Typhoid Fever.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06757283Phase 3Recruiting

Competing Products

7 competing products in Typhoid Vaccination

See all competitors
ProductCompanyStageHype Score
Vi-CRM197 vaccine + Vi Polysaccharide (PS) vaccine + Pneumococcal conjugate vaccineNovartisPhase 2
52
NVGH Vi-CRM197 12.5 mcg + NVGH Vi-CRM197 5.0 mcg + NVGH Vi-CRM197 1.25 mcg + Vi-polysaccharide vaccineNovartisPhase 2
52
Typherix + NVGH Vi-CRM197NovartisPhase 1
33
NVGH Vi-CRM197NovartisPhase 2
52
Vi-CRM197 vaccine + Pneumococcal conjugate vaccine + Vi Polysaccharide (PS) vaccineNovartisPhase 2
52
VivotifBavarian NordicPre-clinical
20
Dose of 5.0 x 10^9 CFU (Cohort 1) + Dose of 7.5 x 10^9 CFU (Cohort 2) + Dose of 1.1 x 10^10 CFU (Cohort 3) + Dose of of 1.7 x 10^10 CFU (Cohort 4)Emergent BioSolutionsPhase 2
44

Other Products from Zydus Lifesciences

SaroglitazarApproved
85
DesidustatApproved
85
Desidustat Oral Tablet + Epoetin AlfaPhase 3
77
Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel + DUAC® Gel + PlaceboPhase 3
77
Pertuzumab (ZRC-3277) + Pertuzumab (Perjeta®)Phase 3
77